Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2014

View Archived Issues

R-Tech Ueno completes phase I/II study of RU-101 for severe dry eye

ArQule collaborates with NIH on development of ARQ-092 in Proteus syndrome

VaxInnate reports topline results from phase I study of quadrivalent influenza vaccine candidate

Daiichi Sankyo selects research collaborations for 2014 TaNeDS drug discovery initiative

Novel anti-PD-L1 therapy shows promise in in vitro and in vivo bladder tumor models

OncoEthix updates on OTX-015 clinical trial program

Intarcia and Servier partner on ITCA-650 outside U.S. and Japan

Alios BioPharma presents preclinical data for novel nucleoside HCV polymerase inhibitors

ScinoPharm and Nanjing King-friend collaborate on Chinese development of regadenoson

GC-021109 receives FDA fast track designation

The Duchenne Alliance provides funds for follistatin gene therapy trial

Novel GPR119 agonists disclosed by Yuhan Corp.

AbbVie prepares new anti-RSV thiazoles

Matinas BioPharma begins dosing in first-in-human trial of MAT-9001

Phase III results presented for liraglutide as weight management drug in adults with obesity

HEP-114 dose-dependently improves liver function in patients with toxic-induced liver injury

E.U. orphan drug designation given to Xeris' soluble glucagon

NNZ-2566 shows clinical benefit phase II Rett syndrome trial

GlaxoSmithKline submits variation to the MAA for Revolade

Boehringer Ingelheim decides not to exercise option for Athera cardiovascular antibody

Highland Therapeutics reports topline data from phase III trial of HLD-200

Phase II SBIR grant supports ONL Therapeutics' development of ONL-101 in retinal detachment

Isis and AstraZeneca to collaborate on targeted delivery of antisense oligonucleotides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...